<DOC>
	<DOCNO>NCT00805025</DOCNO>
	<brief_summary>Over 70-day study period , eligible patient visit study clinic every 2 week ( total 6 visit ) receive 28-day course aztreonam inhalation solution ( AZLI ) . The Quality Life-Bronchiectasis ( QOL-B ) questionnaire complete several time point study , additional pulmonary function test standard procedure .</brief_summary>
	<brief_title>Evaluation Quality Life Questionnaire-Bronchiectasis ( QOL-B ) Patients With Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Written inform consent prior studyrelated procedure Ability read understand English language Bronchiectasis confirm CT scan chest Previous treatment antibiotic bronchiectasis Documented history positive sputum culture gramnegative organism within 5 year Positive sputum culture gramnegative organism first visit ( Day 14 ) Hospitalization hemoptysis &gt; 30 mL within 14 day first visit ( Day 14 ) Antibiotic use respiratory symptom within 14 day first visit ( Day 14 ) , exclude chronic , stable azithromycin use Change corticosteroid bronchodilator regimen within 14 day first visit ( Day 14 ) Forced expiratory volume 1 second ( FEV1 ) &lt; 25 % predict approximately 15 minute follow use bronchodilator first visit ( Day 14 ) Cigarette smoke within 6 month first visit ( Day 14 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>